Helix Biopharma Corp.
HBP.TO
TSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.11% | 74.61% | -185.81% | -101.86% | 27.65% |
| Total Depreciation and Amortization | -51.72% | 31.82% | -24.14% | 31.82% | -24.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 161.71% | -105.91% | 22,657.66% | -70.00% | 128.40% |
| Change in Net Operating Assets | -57.02% | -36.62% | 54.30% | 205.82% | -3.96% |
| Cash from Operations | -4.90% | -15.43% | 34.11% | 25.08% | 18.86% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | 30.51% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 6.78% | 493.33% | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -36.39% | 172,200.00% | -99.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -36.97% | 181,300.00% | -99.96% |
| Foreign Exchange rate Adjustments | -- | -- | 410.17% | 71.50% | -355.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 299.15% | -330.60% | -37.70% | 138.59% | -283.66% |